title: Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist.
abstract: With the long-term aim of developing a new type of therapy for diabetes, we have investigated the reprogramming of liver cells in normal mice toward a pancreatic phenotype using the gene combination Pdx1, Ngn3, MafA. CD1 mice were rendered diabetic with streptozotocin and given a single dose of Ad-PNM, an adenoviral vector containing all three genes. Ad-PNM induced hepatocytes of the liver to produce insulin, and the blood glucose became normalized. But over several weeks, the insulin-positive cells were lost and the blood glucose rose back to diabetic levels. Simultaneous administration of a peroxisome-proliferator-activated receptor agonist, WY14643, caused remission of diabetes at a lower dose of Ad-PNM and also caused the appearance of a population of insulin-secreting ductal structures in the liver. The insulin-positive ducts were stable and were able to relieve diabetes in the long term. We show that the effect of WY14643 is associated with the promotion of cell division of the ductal cells, which may increase their susceptibility to being reprogrammed toward a beta cell fate.
authors.affiliation: Stem Cell Institute, University of Minnesota, MTRF, Minneapolis, MN, USA.
authors.forename: A
authors.initials: A
authors.lastname: Banga
authors.affiliation: Stem Cell Institute, University of Minnesota, MTRF, Minneapolis, MN, USA.
authors.forename: L V
authors.initials: LV
authors.lastname: Greder
authors.affiliation: Stem Cell Institute, University of Minnesota, MTRF, Minneapolis, MN, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Dutton
authors.affiliation: Stem Cell Institute, University of Minnesota, MTRF, Minneapolis, MN, USA.
authors.forename: J M W
authors.initials: JM
authors.lastname: Slack
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics; D001786:Blood Glucose / Q000378:metabolism; D003131:Combined Modality Therapy; D000229:Dependovirus / Q000235:genetics; D003921:Diabetes Mellitus, Experimental / Q000473:pathology / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D018398:Homeodomain Proteins / Q000235:genetics; D007328:Insulin / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000166:cytology*; D008099:Liver / Q000166:cytology / Q000378:metabolism; D051473:Maf Transcription Factors, Large / Q000235:genetics; D051379:Mice; D009419:Nerve Tissue Proteins / Q000235:genetics; D011743:Pyrimidines / Q000008:administration & dosage* / Q000494:pharmacology; D015534:Trans-Activators / Q000235:genetics
chemical_list: D000924:Anticholesteremic Agents; D051792:Basic Helix-Loop-Helix Proteins; D001786:Blood Glucose; D018398:Homeodomain Proteins; D007328:Insulin; D051473:Maf Transcription Factors, Large; D009419:Nerve Tissue Proteins; D011743:Pyrimidines; D015534:Trans-Activators; C485160:Mafa protein, mouse; C407737:Neurog3 protein, mouse; C084010:pancreatic and duodenal homeobox 1 protein; C006253:pirinixic acid